The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for BCLC B and C patients together; (2) full or dose-adjusted sorafenib for BCLC B patients; (3) full or dose-adjusted sorafenib for BCLC C patients. Outcomes include quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). In the base-case analysis dose-adjusted sorafenib was the most effective of the evaluated strategies. For dose-adjusted sorafenib, QALY was 0.44 for BCLC B and C patients together, 0.44 for BCLC C patients, and 0.38 for BCLC B patients. The ICER of dose-adjusted sorafenib compared with BSC was €34,534 per QALY gained for BCLC B and C patients together, €27,916 per QALY gained for BCLC C patients, and €54,881 per QALY gained for BCLC B patients. Results were sensitive to BSC survival rate, and sorafenib treatment duration.

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma / Cammà, Calogero; Cabibbo, Giuseppe; Petta, Salvatore; Enea, Marco; Iavarone, Massimo; Grieco, Antonio; Gasbarrini, Antonio; Villa, Erica; Zavaglia, Claudio; Bruno, Raffaele; Colombo, Massimo; Craxì, Antonio. - In: HEPATOLOGY. - ISSN 0270-9139. - STAMPA. - 57(2013), pp. 1046-1054. [10.1002/hep.26221]

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

VILLA, Erica;
2013

Abstract

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for BCLC B and C patients together; (2) full or dose-adjusted sorafenib for BCLC B patients; (3) full or dose-adjusted sorafenib for BCLC C patients. Outcomes include quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). In the base-case analysis dose-adjusted sorafenib was the most effective of the evaluated strategies. For dose-adjusted sorafenib, QALY was 0.44 for BCLC B and C patients together, 0.44 for BCLC C patients, and 0.38 for BCLC B patients. The ICER of dose-adjusted sorafenib compared with BSC was €34,534 per QALY gained for BCLC B and C patients together, €27,916 per QALY gained for BCLC C patients, and €54,881 per QALY gained for BCLC B patients. Results were sensitive to BSC survival rate, and sorafenib treatment duration.
57
1046
1054
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma / Cammà, Calogero; Cabibbo, Giuseppe; Petta, Salvatore; Enea, Marco; Iavarone, Massimo; Grieco, Antonio; Gasbarrini, Antonio; Villa, Erica; Zavaglia, Claudio; Bruno, Raffaele; Colombo, Massimo; Craxì, Antonio. - In: HEPATOLOGY. - ISSN 0270-9139. - STAMPA. - 57(2013), pp. 1046-1054. [10.1002/hep.26221]
Cammà, Calogero; Cabibbo, Giuseppe; Petta, Salvatore; Enea, Marco; Iavarone, Massimo; Grieco, Antonio; Gasbarrini, Antonio; Villa, Erica; Zavaglia, Claudio; Bruno, Raffaele; Colombo, Massimo; Craxì, Antonio
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1064352
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 78
social impact